Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Stock Trading Plan

6 Oct 2016 18:01

RNS Number : 9410L
GW Pharmaceuticals PLC
06 October 2016
 

Director Stock Trading Plan

London, UK; 6 October 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: "GWP," "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, has today been notified that Mr Justin Gover, its Chief Executive Officer, has established a personal stock trading plan in accordance both with the guidelines established by Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended, and the EU Market Abuse Regulation, as well as the Company's policies with respect to insider sales.

Rule 10b5-1 plans permit directors, officers and other company insiders to adopt, at times when they are not in possession of material, non-public information, written plans for trading securities in a non-discretionary, pre-scheduled manner in the future. These pre-planned trades can then be executed at a later date, as spelled out in the plan, without further action by the director, officer or other company insider and without regard to any subsequent non-public information the individual might have received.

Mr Gover's plan provides for the exercise and sale of options over up to 362,144 Ordinary 0.1p Shares (equivalent to 30,178 American Depository Shares), between 9 December 2016 and 1 April 2017 in order to avoid otherwise adverse personal taxation implications of non-exercise of these options.

Following exercise of these options, Mr Gover will continue to hold 1,067,972 options over Ordinary Shares (equivalent to 88,997 ADSs) and will continue to be the beneficial owner of an additional 2,513,759 Ordinary Shares (equivalent to 209,479 ADSs).

The transactions under the plan will be disclosed publicly through Form 144 and Form 4 filings as required by the U.S. Securities and Exchange Commission, and by announcement through a Regulatory Information Service, as required by the EU Market Abuse Regulation.

For further information, please contact:

 

GW Pharmaceuticals PLC +44 (0)1980 557 000

Adam George, Company Secretary

 

Peel Hunt LLP (Nominated Adviser)

James Steel/Oliver Jackson +44 (0) 20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHQQLFBQBFEFBV
Date   Source Headline
13th Dec 20104:15 pmRNSDirector/PDMR Shareholding
9th Dec 20102:39 pmRNSPublication of Annual Report
8th Dec 20103:52 pmRNSDirector/PDMR Shareholding
3rd Dec 20107:00 amRNSChange of Adviser
29th Nov 20104:31 pmRNSDirector/PDMR Shareholding
23rd Nov 20107:01 amRNSSativex Enters Phase III Cancer Pain Programme
23rd Nov 20107:00 amRNSFinal Results
19th Nov 201010:10 amRNSUpdate on Nomad and Broker Position
3rd Nov 20107:00 amRNSSativex Approved in New Zealand for MS Spasticity
21st Oct 201011:30 amRNSNotice of Results
21st Oct 201011:30 amRNSNotice of Results
14th Oct 20109:30 amRNSResearch Update
13th Oct 201012:12 pmRNSHolding(s) in Company
30th Sep 20107:03 amRNSGW Starts Phase IIa Study Programme
22nd Sep 20107:00 amRNSSativex Study Results Published in Peer Journal
16th Sep 20109:29 amRNSHolding(s) in Company
16th Sep 20109:28 amRNSHolding(s) in Company
14th Sep 20105:16 pmRNSDirector/PDMR Shareholding
9th Sep 201011:51 amRNSDirector/PDMR Shareholding
31st Aug 20107:00 amRNSHealth Canada Grants Full Approval of Sativex
3rd Aug 20107:00 amRNSDirector/PDMR Shareholding
28th Jul 20107:00 amRNSSativex receives regulatory authorisation in Spain
27th Jul 20107:00 amRNSDirectorate Change
23rd Jul 20105:10 pmRNSDirector/PDMR Shareholding
19th Jul 20103:33 pmRNSDirector/PDMR Shareholding
5th Jul 20105:35 pmRNSDirector/PDMR Shareholding
2nd Jul 201010:03 amRNSResponse to Media Comment
30th Jun 20107:00 amRNSGlobal Cannabinoid Research Collaboration Extended
22nd Jun 201011:23 amRNSGW Pharma to present at Piper Jaffray Conference
21st Jun 20107:00 amRNSUK Launch of First Prescription Cannabis-Medicine
18th Jun 20102:33 pmRNSProduct Update
11th Jun 20103:36 pmRNSDirector/PDMR Shareholding
20th May 20107:00 amRNSInterim Results
11th May 20104:21 pmRNSNotice of Results
28th Apr 20104:40 pmRNSSecond Price Monitoring Extn
28th Apr 20104:35 pmRNSPrice Monitoring Extension
31st Mar 20105:28 pmRNSTotal Voting Rights
25th Mar 20104:07 pmRNSDirector/PDMR Shareholding
24th Mar 20105:21 pmRNSHolding(s) in Company
24th Mar 20102:55 pmRNSResult of AGM
23rd Mar 20103:44 pmRNSHolding(s) in Company
23rd Mar 20103:38 pmRNSHolding(s) in Company
23rd Mar 20107:00 amRNSPositive Data in Sativex Phase IIb Trial
18th Mar 20107:00 amRNSSativex Regulatory Update
18th Jan 20105:27 pmRNSBlock Listing Application
15th Jan 201011:09 amRNSTotal Voting Rights
5th Jan 20104:35 pmRNSPrice Monitoring Extension
11th Dec 20098:57 amRNSDoc re. Annual Report
1st Dec 20097:00 amRNSChange of Adviser
26th Nov 20095:46 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.